Meeting
2011 ASCO Annual Meeting
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
Authors
A. Johnsson
Department of Oncology, Skane University Hospital-Lund, Lund, Sweden
A. Johnsson , J. Frodin , A. Berglund , H. Hagman , J. Sundberg , D. Bergstrom , R. d. Christensen , N. Keldsen , K. G. Spindler , A. K. M. Jakobsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00598156
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3526)
Abstract #
3526
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Induction treatment in first-line with chemotherapy + bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study.
First Author: Christophe Tournigand
Poster
2011 ASCO Annual Meeting
The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
First Author: T. Hansen
Poster
2016 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
First Author: Kei Muro
Poster
2019 Gastrointestinal Cancers Symposium
Safety of bevacizumab in cancer patients with inflammatory bowel disease.
First Author: Ruth Gabriela Herrera Gomez